Adding ketamine to opioids doesn't reduce cancer pain

September 11, 2012
Adding ketamine to opioids doesn't reduce cancer pain
Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it is associated with increased toxicity, according to research published online Sept. 10 in the Journal of Clinical Oncology.

(HealthDay)—Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it is associated with increased toxicity, according to research published online Sept. 10 in the Journal of Clinical Oncology.

Janet Hardy, M.D., of the Mater Adult Hospital in South Brisbane, Australia, and colleagues conducted a multisite, dose-escalation, randomized, double-blind, placebo-controlled trial involving 185 patients with advanced cancer to evaluate the use of ketamine or placebo delivered subcutaneously over three to five days. The authors sought to determine whether the addition of ketamine to opioids improves the management of chronic uncontrolled cancer pain.

The researchers observed no significant difference between patients receiving ketamine or placebo, and it did not matter whether pain was nociceptive or neuropathic. However, there were nearly double the adverse events with ketamine compared with placebo, including a greater risk of severe adverse events (odds ratio, 1.09; 95 percent confidence interval, 1.00 to 1.18). For one positive outcome to be achieved with ketamine use, the number needed to treat was 25, compared with a number needed to harm of only six.

"This large demonstrated a strong and failed to show any additional for ketamine when delivered subcutaneously in a dose-escalating regimen over five days, while significantly increasing toxicity," the authors write.

Explore further: Ketamine helps see how the brain works in clinical depression

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Ketamine improved bipolar depression within minutes

May 30, 2012

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide ...

'Special K' could relieve depression

June 7, 2012

(Medical Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in people with severe depression and is providing almost instant relief from symptoms, offering fresh hope of a quick new way to manage the ...

Cannabinoid formulation benefits opioid-refractory pain

June 13, 2012

(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of ...

Recommended for you

New role for an old protein: Cancer causer

September 3, 2015

A protein known to play a role in transporting the molecular contents of normal cells into and out of various intracellular compartments can also turn such cells cancerous by stimulating a key growth-control pathway.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.